Clinical trial
Phase III Study of AK112 for NSCLC Patients
NCT06396065
Study timeline
Study start (actual)2023-05-04Date precision: day
Registry last updated2026-07-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-Squamous Non-small Cell Lung Cancerunresolved
Interventions
AK112 InjectionDRUG
Sponsors & collaborators
Summit Therapeuticslead sponsor
Akesocollaborator
Mapped research locations
MadridSpain5Los AngelesCalifornia, United States3New YorkNew York, United States2BarcelonaSpain2ParisFrance2MilanItaly2SacramentoCalifornia, United States2OrangeCalifornia, United States2HoustonTexas, United States1BostonMassachusetts, United States1DallasTexas, United States1MiamiFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06396065 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.